DC/AML Fusion Vaccine

BIOLOGICAL2 trials

Sponsors

Beth Israel Deaconess Medical Center, David Avigan

Conditions

Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia, in Relapse

Phase 1

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

RecruitingNCT07374029

David AviganAcute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse

Start: 2026-02-12End: 2030-10-01Target: 30Updated: 2026-05-05

Phase 2

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Active, not recruitingNCT03059485

Beth Israel Deaconess Medical CenterAcute Myelogenous Leukemia

Start: 2017-06-01End: 2026-12-04Updated: 2026-02-04

Related Papers

Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Blood2024-11-051 citations